Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [921]

PARP inhibitors olaparib and talazoparib as treatment for metastatic breast...

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

PARP inhibitors olaparib and talazoparib as treatment for metastatic breast cancer ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

The potential of PARP inhibitors in new cancer groups and in combination with...

Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston...

The potential of PARP inhibitors in new cancer groups and in combination with other treatments ( Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA )

Myeloma highlights from EHA 2019

Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain

Myeloma highlights from EHA 2019 ( Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain )

ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in...

Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

$ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in relapsed or refractory CLL ( Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )$

Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable...

Dr Mark Roschewski - National Cancer Institute, Bethesda, USA

Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable responses in R/R DLBCL and indolent lymphoma ( Dr Mark Roschewski - National Cancer Institute, Bethesda, USA )

Acalabrutinib monotherapy shows significant benefit in relapsed or refractory...

Dr Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

$Acalabrutinib monotherapy shows significant benefit in relapsed or refractory chronic lymphocytic leukaemia ( Dr Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )$

CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo...

Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA

CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urothelial carcinoma ( Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA )

Breast cancer highlights from ASCO 2019

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Breast cancer highlights from ASCO 2019 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Proton therapy or photon therapy as part of concurrent chemoradiotherapy for...

Prof Brian Baumann - Washington University in St. Louis, St. Louis, USA

Proton therapy or photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer ( Prof Brian Baumann - Washington University in St. Louis, St. Louis, USA )

Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast...

Dr Zahi Mitri - OHSU Hospital, Portland, USA

Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer ( Dr Zahi Mitri - OHSU Hospital, Portland, USA )

Targeting agent enfortumab vedotin a novel treatment for patients with advanced...

Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA

Targeting agent enfortumab vedotin a novel treatment for patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )

New agent targeting Nectin-4 produces responses in nearly half of patients with...

Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA

New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )

More from ecancer